A 63% year-to-date rally has put Moderna back in the spotlight, but a deeper look at the fundamentals suggests biotech investors may be overlooking a more stable juggernaut in Gilead Sciences.
Back
Gilead's $2.4B cash flow questions Moderna's 63% stock surge
Moderna Inc.’s (NASDAQ:MRNA) impressive 63.17% stock surge in 2026, fueled by a surprise first-quarter revenue beat, is drawing comparisons to the more consistent performance of Gilead Sciences Inc. (NASDAQ:GILD). While Moderna’s top-line growth has captured headlines, its underlying financials—including a projected 40% revenue drop in 2025 and significant cash burn—stand in stark contrast to Gilead’s multi-billion-dollar free cash flow and steady shareholder returns.
Gilead’s strategy is built on durable franchises and a deep pipeline. “We have the strongest pipeline in Gilead’s history… With up to four potential launches and five Phase 3 updates anticipated in 2026,” Gilead CEO Daniel O’Day said, highlighting the company's internally funded growth prospects.
The financial divergence is sharp. Moderna’s Q1 revenue tripled to $389 million, yet the company posted a GAAP net loss of $1.34 billion and expects its cash reserves to fall from $8.1 billion to as low as $4.5 billion by the end of 2026. Conversely, Gilead’s Q1 free cash flow soared 237% year-over-year to $2.427 billion, driven by its HIV franchise which grew 10% to $5.03 billion.
This presents a clear choice for investors: Moderna’s high-risk, high-reward profile tied to binary clinical outcomes, versus Gilead’s model of steady growth, robust cash generation, and direct capital returns. The market’s enthusiasm for Moderna hinges on future pipeline success, while Gilead offers a proven record of profitability and a 2.46% dividend yield.
The Case Against Moderna's Surge
Beyond the headline-grabbing stock chart, Moderna’s financial footing appears less secure. The company’s revenue remains almost entirely dependent on its COVID-19 product, and sales are contracting, with full-year 2025 revenue collapsing to $1.94 billion. Management’s guidance for up to 10% growth in 2026 is off that much lower base.
The cash situation is a primary concern for bears. Projections show cash falling to between $4.5 billion and $5.0 billion by the end of 2026, and the company recently drew $600 million on a credit facility. Unlike Gilead, Moderna returns no capital to shareholders through dividends or buybacks. Upcoming catalysts, including a PDUFA date for its flu vaccine on August 5, 2026, are critical but binary events that do not guarantee a shift to sustainable profitability.
Gilead's Foundation of Cash Flow and Returns
Gilead presents a different picture, one of stability and shareholder focus. The company’s HIV drug Biktarvy, which brought in $3.36 billion in Q1 alone, now has patent protection extended to April 2036, securing a full decade of revenue from a key product. This durable cash flow funds both pipeline development and shareholder returns.
In the first quarter of 2026, Gilead returned $419 million to shareholders via stock repurchases and has a $6.0 billion buyback authorization remaining. The company also declared a quarterly dividend of $0.82 per share. This ability to self-fund its pipeline, which includes a PDUFA date for its BIC/LEN combination on August 27, 2026, and anito-cel for multiple myeloma on December 23, 2026, provides a significant strategic advantage over cash-burning rivals.
The Investor Takeaway
The divergence between Moderna and Gilead offers a clear case study in investor strategy. Moderna’s stock performance reflects a high-beta trade on pipeline hopes, disconnected from current fundamentals of revenue decline and cash burn. Gilead, meanwhile, represents a more traditional biotech investment, with a forward earnings multiple of 15, a steady dividend, and a fortress balance sheet.
While Moderna’s chart is more exciting, Gilead’s quiet compounding and 22.98% gain over the past year, achieved with a low beta of 0.332, may present the more compelling long-term opportunity for retirement portfolios. The choice hinges on an investor’s appetite for risk and their preference for speculative growth versus proven, cash-generating value.
This article is for informational purposes only and does not constitute investment advice.
